Our R&D organization continues to deliver a steady stream of pipeline assets in multiple therapeutic areas with nearly 50 compounds in Exploratory Development. In 2010, greater than 1 in 3 of our compounds in development were biologics or large molecules. And we are pioneering a new drug modality, millamolecular technology, which are midsize between large and small molecules. Compounds in Exploratory Development are in preclinical or early clinical development. Full Development compounds are investigational drugs that are in later-stage clinical development or have been submitted to regulatory agencies for approval. Finally, medicines in Marketed Product Development are driving current and future growth while also undergoing continued clinical development to determine whether additional indications and formulations will benefit patients. For Full development compounds alone, we are conducting nearly 100 clinical trials, enrolling more than 63,000 patients in 47 countries.